Clinical and Research Journal in Internal Medicine

Vol. x No. x, Month Years

e-ISSN: 0000 - 0000 – 0000, p-ISSN: 0000 - 0000 – 0000
Available online at https://crjim.ub.ac.id/index.php/crjim/

Case Report

Title (Leelawadee 13, Capitalise Each Word Case, Dark Blue, Align Left)
First Author1, Second Author2, Third Author3 ( Source Sans Pro 10, Full name without degree, Black, Capitalize
each word Case, Align Left)
1
First Author’s institutional address (Source Sans Pro 8, Black, Align Left, single space).
2
Second Author’s institutional address (Source Sans Pro 8, Black, Align Left, single space).
3
Third Author’s institutional address (Source Sans Pro 8, Black, Align Left, single space).

A R T I C L E I N F O (Source sans pro A B S T R A C T (Source sans pro 10, Blue Accent 1 50%, UPPERCASE, Center)
10, Blue Accent 1 50%, UPPERCASE, Align
Left)

Corresponding Author: (Source Source Sans Pro 9, single space, contains the brief description of the researintroduction ch.
Sans Pro 9, Blue Accent 1 25%, Align Source San Pro 9, single space, contains the brief description of the case.
Left) Source Sans Pro 9, single space, contains the brief description of the case discussion.
Author’s Full Name (Source Sans Pro Source Sans Pro 9, single space, contains the brief description of the case report conclusion.
9, Black, Align Left)
Author’s Institutional Address Keywords: keyword, keyword, keyword, keyword, keyword (Source Sans Pro 9, single space)
Email: (Source Sans Pro 9, Blue Accent
1 25%, Align Left)
Author’s email as the principal contact
(Source Sans Pro 9, Black, Align Left)

https://doi.org/(filled by
editor)
Received on xxx xx, xxxx;
Revised on xxx xx, xxxx;
Accepted on xxx xx, xxxx

Cite this as: Vancouver style

First Author’s last name followed by the initials of first and/or second name, Second Author’s last name followed
by the initials of first and/or second name, Third Author’s last name followed by the initials of first and/or second
name. Article’s title. Publisher. Time of published; Volume (Issue);page. DOI/PubMed lin.
Page | 1
 Author’s name CRJIM x (x): Month Year

I N T R O D U C T I O N (Source Sans Pro

12,
Bold, Dark Blue, UPPERCASE with space
in
every alphabet in 2 Columns) Pagraph is
written using Source Sans Pro 11 with 1,15
space. Each new paragraph indents in 3 pt. The
content of introduction usually is the
background of case report.
Reference cited according to Vancouver, Figure 1. The figure must be written in Source Sans Pro 9,
center, and placed directly below the image
numbered in accordance with the order of
references in the research and in accordance
with the sequence number in the bibliography.
The number is written after dot “.” in
superscript. In writing the citations and
references, authors are recommended to use
reference management software, such as:
Mendeley® or Zotero.
C A S E I L L U S T R A T I O N (Source Sans
Pro 12, Bold, Dark Blue, UPPERCASE Figure 2. Legend must be written in Times New Roman 9,
center, and placed directly below the image
with space in every alphabet) Table 1. Legend should be written in Source Sans Pro 9
The content consists of PATIENT with single space and placed above the table content,
DEMOGRAPHICS in detail, medical record, Align Left. Apply the line only for top and bottom border.
intervention or treatment, result orotther aaaa bbbb cccc
significant information. data collection, data ddddd hhhhh mmmmm
eeeee iiiii nnnnnn
sources such as the population and sample,
fffff jjjjj oooooo
and data analysis.
ggggg kkkkk
Data and information (that subtopic should llllll
be Black and Bold followed by the The Nota Bene should be written in Source Sans Pro 8 with single
space and placed directly below the table content, align left, italic.
description in a next line)
All figures, tables, or informative illustrations
D I S C U S S I O N S (Source Sans Pro 12,
are prepared as HD image file.
Bold, Dark Blue, UPPERCASE with space
in every alphabet)
The content consists of the discussion about
the finding. It should be written using Source
Sans Pro with 1.15 space with single space and
each new paragraph indents in 3 pt.
C O N C L U S I O N (Source Sans Pro 12,

CRJIM • Vol xx• Number x • Month Year Page | 2

 Author’s name
Bold, Dark Blue, UPPERCASE with space
in every alphabet)
Conclusion should clearly state the result of
correlated objective (and may also possible
with future direction). Avoid using point or
numbering. It should be written using Source
Sans Pro with 1.15 space with single space and
each new paragraph indents in 3 pt.
Acknowledgement (Source Sans Pro
12,
old, Dark Blue, UPPERCASE with space in
every alphabet)
It contains the article’s support or sponsorship .
It should be written using Source Sans Pro with
1.15 space with single space and each new
paragraph indents in 3 pt.
References (Source Sans Pro 14, Bold,
Dark Blue. It is written according to
Vancouver, numbered in accordance
with the order of references in the
research and in accordance with the
sequence number in the bibliography.
Please use the reference with the most
recent publishing year)
CRJIM • Vol xx• Number x • Month Year
CRJIM x (x): Month Year
1. First Author’s last name followed by the
initials of first and/or second name, Second
Author’s last name followed by the initials of
first and/or second name, Third Author’s last
name followed by the initials of first and/or
second name. Article’s title. Publisher; Time of
published. Volume(Issue);page. DOI/PubMed
link
2. Mason, RP, Marche P, and Hintze TH. Novel
Vascular Biology of Third-Generation L-Type
Calcium Channel Antagonists Ancillary
Actions of Amlodipine. Arterioscler Thromb
Vasc Biol. 2003; 23(12):2155-63 [PMID:
14512371.
https://doi.org/10.1161/01.ATV.0000097770.6
6965.2A]
3. Pitt B, Byington RP, Furberg CD, et al. Effect
of Amlodipine on the Progression of
Atherosclerosis and the Occurrence of
Clinical Events. Circulation 2000;
102(13):1503-10. [PMID: 11004140.
https://doi.org/10.1161/01.CIR.102.13.1503]
4. Detry J. Amlodipine and the Total Ischemic
Burden: Circadian Anti Ischemia Program in
Europe (CAPE) Trial-Methodology, Safety,
and Toleration. The Steering Committee
Members and All of the Investigators.
Cardiology. 1994; 85 Suppl 2:24-30. [PMID:
7736484. https://doi.org/10.1159/000177044]
Page | 3